EUR 1,2 billion for vaccine deliver


Kvistgard – The U.S. Department of Health and Human Services has awarded a contract to the Danish-German company Bavarian Nordic A/S for the manufacture and delivery of 20 million doses of the company’s third-generation Modifed Virus Ankara (MVA) smallpox vaccine Imvamune for the US’s Strategic National Stockpile.
The overall deal, including options within the contract, is valued a1,2 billion of which the base contract comprises a370 million. Alongside the delivery of 20 million doses, the money is earmarked in part for investment in further research and development of the vaccine, which will fulfil requirements for a potential use of the vaccine during an emergency case. The money will also be used to fund non-clinical and clinical studies that are necessary for Bavarian Nordic to receive a FDA registration for Imvamune as a vaccine for healthy people. A sum of a820 million is included in the optional part of the contract which is intended to support further clinical studies for the extension of Imvamune’s license to include people infected with HIV, children and the elderly, as well as to procure of up to 60 million additional doses of Imvamune. Bavarian Nordic now hopes, the US contract will pave the way for further deals with other governments.



Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...



Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...



Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...



Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...



Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...



Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...



Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...



Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...



Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...



Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2015 BIOCOM

Product of the week



All Events

Current issue

All issues